racine de gingembre

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note, COVID-19

[no scientific data for COVID-19]

Info: see Herb & Supplement Remedy Use in COVID-19 Resources

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

allergic rhinitis

[Insufficient Evidence]

Dose: 500 mg PO qd

anorexia, cancer-related

[Insufficient Evidence]

Dose: 1650 mg PO qd

ARDS

[Insufficient Evidence]

Dose: 40 mg NG tid

COPD

[Insufficient Evidence]

Dose: 10 mL (100 mg) syrup PO tid; Info: given in 100 mL warm water

COVID-19

[Insufficient Evidence]

Dose: 1-1.5 g PO bid

diabetes mellitus

[Insufficient Evidence]

Dose: 1.2-3 g/day PO divided qd-tid

dysmenorrhea, adult pts

[Possibly Effective]

Dose: 200-250 mg PO qid; Alt: 500 mg PO qd-tid; Start: up to 2 days before menstrual cycle

dysmenorrhea, peds pts

[Possibly Effective]

Dose: 250 mg PO tid in pts 15-18; Start: 1 day before menstrual cycle

dyspepsia

[Insufficient Evidence]

Dose: 1.2 g PO qd; Info: given 60min before meal

erectile dysfxn

[Insufficient Evidence]

Dose: 250 mg PO bid

hangover

[Insufficient Evidence]

Dose: 6 g PO x1; Info: given 5h prior to alcohol consumption; may repeat 6 g PO bid x2 days

hepatotoxicity, toxin-induced

[Insufficient Evidence]

Dose: 500 mg PO qd

hyperlipidemia

[Insufficient Evidence]

Dose: 1 g PO tid; Alt: 200-3000 mg PO qd

hypothyroidism

[Insufficient Evidence]

Dose: 500 mg PO bid

IBS

[Insufficient Evidence]

Dose: 150 mg PO tid

joint pain

[Insufficient Evidence]

Dose: 50 mg/day PO divided tid

menorrhagia

[Insufficient Evidence]

Dose: 250 mg PO tid x4 days; Start: 1 day before menstrual cycle

migraine, acute

[Insufficient Evidence]

Dose: 250-400 mg PO x1; Start: at onset of headache

multiple sclerosis

[Insufficient Evidence]

Dose: 500 mg PO tid

nausea/vomiting, antiretroviral-related

[Insufficient Evidence]

Dose: 500 mg PO bid; Info: given 30min before antiretroviral dose

nausea/vomiting, gastroenteritis-related, peds pts

[Insufficient Evidence]

Dose: 20 gtt (10 mg) ginger liquid PO x1, then cont. q8h until vomiting cessation; Info: for pts 1-10 yo

nausea/vomiting, intraop

[Insufficient Evidence]

Dose: 1 g PO x1 given 30min before anesthesia

nausea/vomiting, postop

[Insufficient Evidence]

Dose: 1-2 g PO x1 given 30-60min before anesthesia, then 1 g PO x1 given 2h after surgery; Alt: apply 5% ginger essential oil to wrists for inhaled aromatherapy before surgery; ginger oil diffused for inhaled aromatherapy x3 postop

nausea/vomiting, pregnancy-related

[Possibly Effective]

Dose: 500-2500 mg/day PO divided bid-qid; Alt: 250 mg PO qid

nonalcoholic fatty liver dz

[Insufficient Evidence]

Dose: 1500 mg PO qd; Alt: 1000 mg PO bid

osteoarthritis

[Possibly Effective (PO route)]

Dose: 500-1000 mg PO qd; Alt: 170 mg PO tid; 340 mg PO qd; 30 mg PO qd

[Possibly Effective (topical route)]

Dose: apply 1 g (4-5% gel) topically tid-qid; Alt: apply ointment topically bid

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 500 mg PO tid

postop recovery

[Insufficient Evidence]

Dose: 500 mg PO bid

postpartum complications

[Insufficient Evidence]

Dose: 500 mg PO x1 given 8h postpartum, then 250 mg PO q8h x1 day

rheumatoid arthritis

[Insufficient Evidence]

Dose: 1500 mg PO qd

smoking cessation

[Insufficient Evidence]

Dose: 25 mg PO qd

swallowing dysfxn

[Insufficient Evidence]

Dose: apply spray topically to oropharynx qd

traumatic brain injury

[Insufficient Evidence]

Dose: 36 mg PO tid; Info: used w/ boswellia

ulcerative colitis

[Insufficient Evidence]

Dose: 1000 mg PO bid

vertigo

[Insufficient Evidence]

Dose: 1 g PO x1

xerostomia

[Insufficient Evidence]

Dose: 20 mL (25% mouthwash) swish/spit tid